Navigating the challenging landscape of legal procurement for controlled substances, specifically Schedule I drugs, represents a particularly unique area for licensed national institutions—typically scientific facilities—and demands meticulous adherence to stringent regulations. This process goes far beyond standard supplier selection, encompas